Most telehealth operators think about recalls the way they think about fire drills: a process they hope never to run. But drug alerts land somewhere in UK pharmacy several times a month, and when one names a batch your dispensing pharmacy has handled, the clock starts immediately. How that gets caught, actioned, and evidenced is one of the clearer tests of whether a dispensing setup is genuinely pharmacy-grade or just fast at printing labels.
What a Drug Alert actually is
An MHRA Drug Alert is a formal notice issued when a medicine, medical device, or specific batch is found to be defective, mislabelled, contaminated, or otherwise unsafe to remain in supply. It isn't the same thing as a general safety update or a prescribing caution — an alert is an instruction to act on specific stock, identified by product name, batch number, and expiry date.
Alerts can be issued by the MHRA itself or as a company-led recall coordinated with the regulator, and they cover the full supply chain: manufacturers, wholesalers, and dispensing pharmacies, including those supplying online prescribing services. A telehealth brand doesn't receive these directly in most cases — the obligation sits with the registered pharmacy actually holding and dispensing the stock, which is one more reason the choice of dispensing partner matters more than it first appears.
The four alert classes, and why the class sets your clock
Drug Alerts are graded by urgency, and the class determines how fast a pharmacy is expected to act and how far the response needs to reach:
- Class 1 — potentially life-threatening or serious risk to health; action is required immediately, often within hours.
- Class 2 — could cause mistreatment or harm but isn't immediately life-threatening; action is typically expected within a short, defined window, commonly measured in days rather than weeks.
- Class 3 — unlikely to cause significant harm but still requires stock to be identified and removed from supply.
- Class 4 — caution in use, often a labelling or information issue rather than a safety defect in the medicine itself.
The class also decides whether the response stops at the pharmacy shelf or has to reach patients who've already taken the medicine home — which is where recalls in a telehealth model get materially harder than in a walk-in high-street pharmacy.
How alerts actually reach a dispensing pharmacy
Registered pharmacies receive Drug Alerts through the MHRA's distribution channels to the sector, reinforced by wholesalers and manufacturers notifying their direct customers when a batch they've supplied is affected. In practice, most dispensing pharmacies also lean on trade body bulletins and their pharmacy management system flagging batch numbers against what's currently in stock.
For a telehealth operator, the practical question isn't whether the pharmacy gets the alert — it almost always does — but how quickly that alert turns into a batch-level stock check against dispensed and undispensed inventory. A pharmacy handling cold-chain products or high volumes of a single line is more exposed if that check isn't near-instant, simply because more patients may already hold the affected batch.
The class of a Drug Alert sets the clock, but the real bottleneck is almost always whether dispensing records are searchable by batch number in minutes — not whether the pharmacy received the alert.
Building an internal response process that survives a Class 1
A recall procedure that only exists on paper falls apart under time pressure. The pharmacies that handle this well treat it as a rehearsed sequence rather than a one-off scramble:
- Log the alert and identify the exact batch numbers and expiry dates affected.
- Search dispensing records for every patient who received stock from an affected batch.
- Quarantine any remaining stock immediately, physically separated from saleable inventory.
- Escalate to the superintendent pharmacist for a decision on patient contact, in line with the alert's class.
- Notify affected patients where the class requires it, with clear, non-alarming instructions.
- Record every step — who was contacted, when, and what was actioned — for later inspection.
The gap most operators discover the hard way is step two: dispensing records that aren't reliably searchable by batch number turn a same-day response into a multi-day one, and the class of the alert doesn't wait for that lookup to catch up.
Telling patients: what's expected, and what to avoid
For higher-class alerts where patients may already hold affected stock, the pharmacy — not the telehealth brand's marketing or support team — leads the clinical communication. GPhC standards expect pharmacy owners to have systems in place to manage recalls safely, and CQC-registered services face the same expectation as part of safe medicines management under their inspection framework.
The message to patients needs to be plain: what the issue is, what to do with the medicine (stop using it, don't dispose of it in normal waste, return it via a specified route), and who to contact with questions. Overstating the risk causes unnecessary alarm; understating it is worse. Where a patient may have already taken a dose, that detail should route to a clinician for individual advice rather than being handled as a generic support ticket, and any adverse reaction should be captured through the pharmacy's pharmacovigilance process and reported via Yellow Card where relevant.
A recall procedure that only exists on paper is not a recall procedure. It's a hope.
Recordkeeping: the part that gets checked later
A recall isn't finished when the stock is quarantined — it's finished when there's a complete, timestamped record of what happened, held in line with the pharmacy's standard records retention practice. Inspectors reviewing a recall after the fact want to see the alert, the batch search results, the quarantine log, the escalation decision, and the patient contact record, not a verbal account of what was done.
Recalls also show up, directly or indirectly, in MHRA's wider enforcement attention on the sector — a pharmacy that can't evidence a recall response quickly becomes a pharmacy that gets asked harder questions about everything else, a pattern that lines up with broader enforcement trends operators are already navigating.
How PExpo's dispensing layer handles recalls
PExpo's dispensing partners run batch-traceable records against every dispensed item as standard, which means a Drug Alert can be checked against actual patient-level dispensing history in minutes rather than being reconstructed manually from delivery notes. The quarantine, escalation, and patient-notification steps sit with the registered pharmacy's clinical governance, exactly as GPhC standards require — PExpo doesn't sit between a pharmacist and a recall decision.
For brands, the practical benefit is less about the recall itself and more about not discovering, mid-crisis, that the dispensing setup underneath the brand can't answer a simple question fast: who has this batch. That's infrastructure worth checking before it's needed, not after.
Recalls are rare enough that it's tempting to deprioritise the process behind them — until a Class 1 alert lands on a Friday afternoon naming a batch your pharmacy actually holds. The operators who handle it calmly are the ones who treated batch traceability as a baseline requirement of their dispensing partner from day one, not a feature to ask about later. If you're evaluating that setup, our pricing and clinic pages set out how PExpo's dispensing layer is structured.
Frequently asked questions
Who is responsible for actioning an MHRA Drug Alert in a telehealth model?
The registered dispensing pharmacy holding the stock is legally responsible for actioning the alert, under the superintendent pharmacist's oversight. A telehealth brand isn't the addressee of the alert, but it should confirm its dispensing partner has a documented, rehearsed recall process — this sits behind the brand's own reputation even though the legal duty is the pharmacy's.
Do patients always need to be contacted about a recall?
Not always — it depends on the alert's class and whether patients may already hold affected stock. Lower-class alerts are often resolved by removing stock from the pharmacy's own supply. Higher-class alerts, especially where a safety risk exists for medicine already dispensed, typically require direct patient contact led by the pharmacy's clinical team.
How quickly must a pharmacy act on a Class 1 alert?
Class 1 alerts require immediate action given the potential for serious harm, and pharmacies are expected to respond without delay. The exact timeframe can vary by alert, so the operative detail is always in the alert notice itself — the safe assumption for any telehealth operator is to treat Class 1 as a same-day, not same-week, obligation.
